Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Assets for 12 consecutive years, with $519.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 42.36% to $519.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $519.0 million, a 42.36% increase, with the full-year FY2024 number at $382.9 million, down 24.09% from a year prior.
  • Assets was $519.0 million for Q3 2025 at ImmunityBio, up from $402.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $519.0 million in Q3 2025 to a low of $209.4 million in Q1 2021.
  • A 5-year average of $373.3 million and a median of $364.6 million in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: surged 111.81% in 2021, then fell 24.19% in 2025.
  • ImmunityBio's Assets stood at $468.9 million in 2021, then decreased by 22.72% to $362.4 million in 2022, then soared by 39.21% to $504.5 million in 2023, then fell by 24.09% to $382.9 million in 2024, then skyrocketed by 35.53% to $519.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Assets are $519.0 million (Q3 2025), $402.1 million (Q2 2025), and $303.8 million (Q1 2025).